4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
The presentation will also be available on the 4DMT website: Preclinical data for 4D-710 for cystic fibrosis lung disease in combination with CFTR modulators to be presented in a poster presentation
4d分子治療學將在廣告海報上展示4D-710用於囊性纖維化肺病與CFTR調節劑的臨床前數據
EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced a poster presentation at the 2024 North American Cystic Fibrosis Conference (NACFC) in Boston, Massachusetts on September 26-28, 2024.
加州艾默裏維爾，2024年9月23日（全球新聞社）--4d分子治療學（納斯達克：FDMt，4DMt或該公司），一家領先的臨床試驗階段遺傳藥公司，專注於發掘遺傳藥物治療大型市場疾病的全部潛力，今日宣佈將在2024年北美囊性纖維化會議（NACFC）上展示廣告海報，該會議將於2024年9月26日至28日在馬薩諸塞州波士頓舉行。
2024 NACFC Poster Presentation Details:
2024 NACFC海報展示詳細信息：
| Title: | Transgene expression and CFTR channel function in human bronchial epithelial cells following addition of CFTR modulators and 4D-710 |
| Poster Session: | Poster 344 |
| Date/Time: | Friday, September 27, 2024 (1:15 – 2:15 p.m. ET) |
| Presenter: | Melissa A. Calton, Ph.D., VP, Early-Stage Product Development at 4DMT |
| 標題： | 添加CFTR調節劑和4D-710後，人支氣管上皮細胞中的轉基因表達和CFTR通道功能 |
| 海報展示會： | 海報344 |
| 日期/時間: | 2024年9月27日星期五 (美國東部時間 下午1:15 - 2:15) |
| 報告人： | Melissa A. Calton, 博士, 4d molecular therapeutics早期產品開發副總裁 |
The presentation will also be available on the 4DMT website:
該演示文稿還可在4DMT網站上查看
About 4DMT
關於4DMT
4DMT is a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT's proprietary invention platform, Therapeutic Vector Evolution, combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our product design, development, and manufacturing engine helps us efficiently create and advance our diverse product pipeline with the goal of revolutionizing medicine with potential curative therapies for millions of patients. Currently, 4DMT is advancing six clinical-stage and one preclinical product candidate, each tailored to address rare and large market diseases in ophthalmology, pulmonology and cardiology. In addition, 4DMT is also advancing programs in CNS through a gene editing partnership. 4D Molecular Therapeutics, 4DMT, Therapeutic Vector Evolution, and the 4DMT logo are trademarks of 4DMT.
4DMt是一家領先的臨床遺傳藥物公司，專注於釋放眼科和肺病領域遺傳藥物治療大型市場疾病的全部潛力。4DMT的專有發明平台 Therapeutic Vector Evolution 將諾貝爾獎獲獎技術定向進化的力量與近十億個合成 AAV 殼體派生序列相結合，以發明用於我們的全資和合作產品候選人的定製和演變載體。我們的產品設計、開發和製造引擎幫助我們高效地創建和推進我們多樣化的產品管道，旨在以潛在的治癒療法革新醫學，服務於數百萬患者。目前，4DMt正在推進六個臨床階段和一個臨床前產品候選人，每個產品都旨在治療眼科、肺病和心臟病等罕見和大型市場疾病。此外，4DMt 也通過基因編輯合作推進了中樞神經系統計劃。4D分子治療、4DMt、治療載體進化和 4DMt 徽標均爲 4DMt 的商標。
All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.
我們所有的產品候選者都處於臨床或臨床前階段，並尚未獲得美國食品和藥物管理局（FDA）或任何其他監管機構的營銷批准。對於它們正在研究的治療用途的安全性或有效性，不發表任何聲明。
Learn more at and follow us on LinkedIn.
了解更多信息，請訪問並在LinkedIn上關注我們。
Contacts:
聯繫人：
Media:
媒體：
Katherine Smith
Inizio Evoke Comms
Media@4DMT.com
凱瑟琳·史密斯
Inizio Evoke Comms
Media@4DMt.com
Investors:
投資者：
Julian Pei
Head of Investor Relations and Corporate Finance
Investor.Relations@4DMT.com
朱利安·裴
投資者關係和企業財務負責人
Investor.Relations@4DMT.com
譯文內容由第三人軟體翻譯。